Purchase Order 36C25926P0315

The Department of Veterans Affairs' Veterans Integrated Service Network 19 (VISN 19) awarded a firm fixed-price purchase order valued at $49,748.73 to Novocure Inc. on March 5, 2026, for the provision of OPTUNE cancer treatment systems. The purchase order, which carries no set-aside designation, is scheduled for completion by June 5, 2026, with performance at the Portsmouth, New Hampshire VA Medical Center. Novocure Inc., a medical device manufacturer specializing in Tumor Treating Fields (TTFields) technology, serves as the prime contractor with no subcontractor involvement, ensuring direct control over its proprietary cancer treatment devices.

This award is issued under Novocure's existing Federal Supply Schedule contract (FSS-65-II-A) for Medical Equipment and Supplies with the VA Veterans Health Administration, a $28.85 million multiple-award vehicle established November 1, 2022, and extending through October 31, 2027. The OPTUNE system represents a non-invasive therapeutic option for solid tumor cancers, including FDA-approved applications for glioblastoma and mesothelioma. As the sole source provider of this specialized technology, Novocure has issued over 100 delivery orders and purchase orders across numerous VISNs, demonstrating the VA's strategic commitment to expanding veterans' access to innovative cancer treatment capabilities throughout the Veterans Health Administration network.